Analyst Upgrades

• Siemens (SI) to buy from hold at Deutsche Bank.
• Diamond Offshore (DO) to market perform from underperform at FBR Capital.
• MeadWestvaco (MWV) to conviction buy from neutral at Goldman.
• TD AmeriTrade (AMTD) and Cabot Oil & Gas (COG) to buy from neutral at BofA/Merrill.
• Janus Capital (JNS) to hold from sell at Citigroup.
• Motorola Mobility (MMI) to buy from neutral at UBS.
• Frontier Communications (FTR) to neutral from underperform at Macquarie.
• Humana (HUM) to buy from hold at Argus.

Analyst Upgrades

• Medicis (MRX) to overweight from neutral at Piper Jaffray, to outperform from market perform at Bernstein, to outperform from sector perform at RBC Capital and to overweight from neutral at JPMorgan.
• Wellpoint (WLP) to buy from neutral at Davenport.
• Humana (HUM) to buy from hold at Jefferies.
• Frontier Oil (FTO) to equal weight from underweight and Resources Connection (RECN) to overweight from equal weight at Barclays.

Here are some highlights from this past week's earnings coverage from BloggingStocks:

• Aeropostale Inc. (NYSE: ARO) strong Q3 results beat estimates despite the dismal retail environment.
• Alpha Natural Resources Inc. (NYSE: ANR) lowered its full-year forecast due to lower demand for coal.
• America's Car-Mart Inc. (NASDAQ: CRMT) reported higher Q2 earnings and higher same-store sales.
• Beazer Homes USA Inc. (NYSE: BZH) losses in Q4 more than tripled as revenue declined.
• Collective Brands Inc. (NYSE: PSS) Q3 profits were in line with estimates, enough to send shares higher.
• General Electric Co. (NYSE: GE) cut its Q4 earnings forecast, which now falls in line with estimates.
• Goldman Sachs Group Inc. (NYSE: GS) warned that it may see its first quarterly loss ever in Q4.
• Guess? Inc. (NYSE: GES) strong Q3 results beat estimates but offered a conservative outlook.
• Infineon Technologies AG (NYSE: IFX) posted a wider Q4 loss on restructuring and warned of further losses.
• Johnson & Johnson (NYSE: JNJ) 2009 earnings are expected to be diluted by an acquisition.
• Marvell Technology Group Ltd. (NASDAQ: MRVL) reported strong Q3 numbers, sending shares higher.
• Medicis Pharmaceutical Corp. (NYSE: MRX) earnings prospects after a settlement led to an analyst's upgrade.
• Merck & Co. Inc. (NYSE: MRK) lowered its 2009 earnings guidance below analysts' expectations.
• Palm Inc. (NASDAQ: PALM) said that it expects Q2 revenues to come in below analysts' estimates.

MOST NOTEWORTHY: Broadcom Corp (BRCM) and American Medical Systems Holdings (AMMD) were today's notable initiations.

• Merrill Lynch reinstated Broadcom Corp (NASDAQ: BRCM) with a Buy rating and $42 target to reflect the company's secular growth story.

• Thomas Weisel started American Medical Systems Holdings (NASDAQ: AMMD) with an Overweight rating and $16 target; the firm says American Medical is a leader in surgical urology and gynecology and sees upside from the company's full pipeline.

OTHER INITIATIONS:

• NaviSite inc (NASDAQ: NAVI) was initiated with a Market Weight rating at Thomas Weisel.

• Medicis Pharmaceutical Corp (NYSE: MRX) was initiated with a Buy rating and $45 target at Jefferies.

• Soleil initiated Amylin Pharmaceuticals Inc (NASDAQ: AMLN) with a Hold rating.

• DA Davidson started Allegheny Technologies Inc (NYSE: ATI) with a Buy rating.

Analyst summaries provided by TheFlyOnTheWall.com (subscription required).

Back on October 23, 2006 investment guru Jim Cramer came out strongly against Bare Escentuals (NASDAQ: (GS) BARE). I pitted my opinion against Cramers and "let it ride". I've just finished doing a cursory check on Bare Escentuals to see how they have fared. Suffice it to say, I hope no one sold their BARE shares based on Cramers advice.

The chart attached herein shall provide the whole story. My words are really not needed. Besides, I'm just a dude living up here in the woods and making cabinet panels for a living. What could I possibly know about investing? Bare Escentuals just went public in September of this year. Their performance thus far appears healthy to me.

The two stocks that Cramer liked in place of Bare Escentuals were Allergan (NYSE: AGN) and Medicis Pharmaceutical (NYSE: MRX). I will concede to Cramer that those two stocks have moved upward also. My point here is small and simple: You don't need a television crew and a stable of financial analysts to pick a winner now and then. If you have good instincts and the willingness to do your own research, you too can pick some stocks which will pay you to own. To quote my bald headed nemesis: "Do your homework."

(Image courtesy of Norton Sales)

Jim Cramer, never one to rest on a single industry segment, discussed the quest for youthfulness tonight on his ever-popular MAD MONEY show.

If you want your body to look like a teenager's but your bank balance to scream "old fogey," Cramer advises that you avoid Bare Escentuals, Inc. (NASDAQ:BARE). He calls it a fad that isn't going anywhere, and says if you own it you should "ring the register." It was spun off by an LBO firm, but now it's too late; the company won't make you money. Cramer had regrets over this one: he didn't tell a caller on Friday to sell, and wished he had.

Better options if you want to capitalize on America's quest for eternal youth? Cramer likes Allergan, Inc. (NYSE:AGN) for its Botox and Medicis Pharmaceutical Corporation (NYSE:MRX) for its competing product. He counselled against the big, luxury names in the space: Avon Products Group (AVP), The Estee Lauder Co. (NYSE:EL) or Revlon, Inc. (NYSE:REV). Cosmetic companies are unreliable to Cramer.

Cramer did say International Flavors & Fragrances Inc. (NYSE:IFF) is a good alternative, even though it is close to a 52-week high. He thinks the company is much better with scents and steady end markets. Soon it will split into two businesses, he says, as it creates sweet ingredients that it sells to large companies like P&G. He said IFF only trades at 16x forward earnings and it has consistent 10% earnings growth. The best pick of the bunch? IFF, Cramer says.

[Photo Michael McCauslin]

MOST NOTEWORTHY: Global Payments Inc. (GPN) and Medicis Pharmaceutical Corporation (MRX) top today's modest list of upgrades. J.P. Morgan upgraded Global Payments to Overweight from Neutral citing concerns over margins being overdone and the possibility guidance could be conservative. Medicis Pharma was upgraded by Credit Suisse to Outperform from Underperform based on increased expectations for Solodyn and increased confidence in Restylane growth.

OTHER UPGRADES: Red Hat Inc. (RHAT) was upgraded to Buy from Hold at Rochdale. And finally, the Banc of America upgraded Agrium (AGU) to Neutral from Sell, citing improved margins and volumes in nitrogen for the change.

Analyst summaries provided by TheFlyOnTheWall.com (subscription required).